The first four bellwether trials in the Xarelto multi-district litigation (“MDL”) have been hand-picked by Louisiana District Judge Eldon Fallon. Out of the over 7,200 lawsuits filed against the blood thinner's manufacturers Johnson & Johnson and Bayer HealthCare, Judge Fallon first selected a case involving a man who suffered gastrointestinal bleeding after taking Xarelto for only a few weeks, and picked a second involving a woman who used Xarelto for a month before she died from cerebral hemorrhage. Those two trials will take place in Louisiana. The third trial will take place in Mississippi and involves a woman who experienced gastrointestinal bleeding while the fourth will occur in Texas on behalf of a man who died while taking Xarelto for atrial fibrillation.
The cases all similarly allege that Xatrelto’s manufacturers marketed the drug as superior to generic versions of the anticoagulant and downplayed the facts that the lack of blood monitoring increased the risk of major bleeding events and that no reversal agent exists to stop life-threatening bleeding. The Xarelto MDL trials are expected to begin in February 2017. Grant & Eisenhofer, a plaintiffs’ law firm involved in the Bellwether Selection Committee and co-lead of the Law & Briefing Committee of the Xarelto MDL, has filed numerous complaints on behalf of individuals who have suffered from Bayer and Johnson & Johnson’s alleged negligence. If you or a loved one experienced complications from taking the drug Xarelto, please call us at 888-207-0382 for a confidential evaluation of your potential claim.